

Amendments to the Specification:

Please replace the paragraphs starting at page 1, line 3:

[ACKNOWLEDGMENTS]

This invention was supported in part by grants from the National Institutes of Health grant number 1 R01 DK 43787 and 5 R01 DK 41842. The U.S. Government may have certain rights in this invention.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of the following provisional applications: United States Ser. No. 60/008,540 and 60/008,543, filed December 13, 1995, and Ser. No. 60/008,606, filed December 14, 1995. This application claims the benefit of the following U.S. patent application: United States Ser. No. 08/764,870, filed December 13, 1996.]
with the following amended paragraphs:

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to and benefit of prior U.S. Provisional Application number 60/008,540, filed December 13, 1995, prior U.S. Provisional Application number 60/008,543, filed December 13, 1995, and prior U.S. Provisional Application number 60/008,606, filed December 14, 1995. This application is a continuation of U.S. patent application 09/637,132, which is a divisional application of U.S. application number 08/980,115, which is a continuation in part of U.S. application number 08/764,870; priority to and benefit of each of which is claimed by this application. The full disclosures of each of these prior applications are incorporated herein by reference.

ACKNOWLEDGMENTS

This invention was supported in part by grants from the National Institutes of Health grant number 1 R01 DK 43787 and 5 R01 DK 41842. The U.S. Government may have certain rights in this invention.

Please replace the paragraph at page 6, line 3 [**FIG. 3** shows the aligned amino acid sequences of the ligand binding domains of several members of the nuclear receptor superfamily.]

with the following amended paragraph:

FIGS. 3A-3R show the aligned amino acid sequences of the ligand binding domains of several members of the nuclear receptor superfamily.

Please replace the paragraph at page 6, line 31 [**FIG. 14** is the synthetic scheme for preparation of TS10.]

with the following amended paragraph:

FIGS. 14A-14B show a synthetic scheme for preparation of TS10.

Please replace the paragraph at page 7, line 4 [**FIG. 17** depicts a Scatchard analysis of labelled T₃ binding to human TR- α and TR- β .]

with the following amended paragraph:

FIGS. 17A-17B depict a Scatchard analysis of labeled T₃ binding to TR- α and TR- β .